Seriderm partners with Cynosure Lutronic to bring energy-based aesthetics to UK

Cynosure Lutronic, the global manufacturer of energy-based aesthetic and medical devices, has entered into a long-term strategic commercial collaboration with Seriderm, an international distributor and service partner for aesthetic medicine professionals.

The agreement formalises and expands a partnership that now spans the UK, Ireland, France and North Africa, strengthening Cynosure Lutronic’s route to market while deepening Seriderm’s position as a key industrial partner to clinics and physicians.

The collaboration follows the merger of US-based Cynosure and South Korea’s Lutronic earlier this year, which created what the group describes as the world’s largest industrial platform dedicated to energy-based devices used in aesthetic and dermatological treatments.

Under the new framework, Seriderm will support healthcare professionals with access to Cynosure Lutronic’s broad portfolio of technologies, alongside technical, clinical and commercial services across its territories.

The partnership builds on a commercial relationship first established in 2019 between Seriderm and Lutronic and now represents a contractual commitment in excess of $100 million.

Nadav Tomer, CEO of Cynosure Lutronic, said: "This strategic cooperation with Seriderm is based on strong mutual trust and the robustness of a model we have built together. It reflects our shared commitment to developing durable, structured commercial relationships between independent organisations that create long-term value for health care professionals."

Hauke Harms, President of International at Cynosure Lutronic, highlighted the longevity of the relationship, noting that it has been shaped by "shared successes since 2019" and close collaboration between teams.

Seriderm, which works with nearly 6,000 physician partners and supports more than 8,000 medical devices in operation globally, operates as a full-service partner to aesthetic clinics, providing equipment, training, education and ongoing clinical support.

CEO Djamel Kemiche described the expanded partnership as "a key milestone" in Seriderm’s development, marking the start of a new growth phase.

The announcement also coincides with Seriderm’s continued investment in the UK market, including the opening of a new headquarters in London’s Primrose Hill. The multi-use space is designed to act as a hub for training, demonstrations and education, showcasing its portfolio of aesthetic technologies.